Home Investing Why we’re lowering our Bristol Myers price target despite an earnings beat, guidance raise

Why we’re lowering our Bristol Myers price target despite an earnings beat, guidance raise

by admin

Shares of Bristol Myers Squibb fell modestly after the drugmaker’s better-than-expected first-quarter results.

You may also like

Leave a Comment

twelve + five =